Journal
NPJ BREAST CANCER
Volume 7, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41523-021-00332-7
Keywords
-
Categories
Funding
- Kom Op Tegen Kanker
- Fonds Nadine De Beauffort
- Investigator Initiated Studies Program of Merck Sharp Dohme Corp.
- ERC [101003153]
- Belgian Cancer Foundation [C/2020/1441]
- Luxemburg Cancer Foundation [FC/2018/07]
- FWO [G059821N]
- Klinsche Onderzoek en OpleidingsRaad (KOOR) of the UHL
- European Research Council (ERC) [101003153] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The study compared the tumor immune microenvironment between TNBC and hormone receptor-negative HER2-positive breast cancer, showing comparable results that may have implications for the use of immune checkpoint inhibition in patients with hormone receptor-negative HER2-positive breast tumors.
The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available